Floatz logo

Cediranib

Papillary Thyroid Cancer

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Papillary Thyroid Cancer cohort.

Asset / SponsorPhaseRating
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Entrectinib
Hoffmann-La Roche
Phase 2CCC
Irinotecan
Famewave Ltd.
Phase 1/2CCC
Nivolumab
Famewave Ltd.
Phase 1/2CCC
ANTI-CEACAM1 MONOCLONAL ANTIBODY CM-24
Famewave Ltd.
Phase 1/2CCC

View all 13 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →